Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00619099 · ClinicalTrials.gov registry record · Phase 2
A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
A Phase 2 study of Myelodysplastic Syndrome, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
- 4
- Study locations
NCT00619099 is a Phase 2 study of Myelodysplastic Syndrome that has completed, run by Eisai. The registered enrollment target is 67 participants, below the 207-participant average among 134 other Myelodysplastic Syndrome trials with a reported enrollment target (68% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT00619099, a Phase 2 study of Myelodysplastic Syndrome, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to determine the effectiveness and safety of two different dose schedules of DACOGEN® (decitabine) for Injection in patients with Myelodysplastic Syndromes (MDS).
Conditions Studied
Interventions
- DRUG decitabine
Study Locations (4)
Ohio
- Gabrail Cancer Center - Canton
Rhode Island
- Landmark Medical Center - Woonsocket
Tennessee
- Sarah Cannon Research - Nashville
Texas
- M. D. Anderson - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2008-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00619099
The ClinicalTrials.gov registry entry for NCT00619099 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 207-participant average among 134 other Myelodysplastic Syndrome trials with a reported enrollment target (68% lower). The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myelodysplastic Syndrome appearing as the primary indexed condition, and to 1 intervention - of which decitabine is the first listed.
NCT00619099 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Ohio, Rhode Island, Tennessee.
Frequently Asked Questions
What is clinical trial NCT00619099 about?
NCT00619099 is a clinical study titled "A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)". The purpose of this study is to determine the effectiveness and safety of two different dose schedules of DACOGEN® (decitabine) for Injection in patients with Myelodysplastic Syndromes (MDS).
What is the current status of trial NCT00619099?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2008-05.
What conditions does trial NCT00619099 study?
This clinical trial studies the following conditions: Myelodysplastic Syndrome.
What interventions are being tested in trial NCT00619099?
The interventions under investigation include: decitabine (DRUG).
Who is sponsoring clinical trial NCT00619099?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00619099 being conducted?
This trial has 4 study locations across Ohio, Rhode Island, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant
RECRUITING · Phase 2
-
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
RECRUITING · Phase 2
-
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
RECRUITING · Phase 2
-
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
RECRUITING · Phase 2
-
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.